![](/fileadmin/_processed_/csm_HIV__63e20764dc.jpg)
Naobios and Sumagen partner to develop HIV vaccine
Under the contract, Naobios SAS will provide bioprocess development and GMP production of clinical batches of a virus-based HIV vaccine candidate...
![](/fileadmin/_processed_/csm_Microglia_and_neurons_c__Gary_Shaw_ed89bb0973.jpg)
Researchers identify blockers of CNS effects of PD1 cancer therapy
In mouse models, a group headed by Marco Prinz from University Freiburg demonstrated that adverse side effects of immune cancer therapies with PD1...
![](/fileadmin/_processed_/csm_Neuroblastom_Primary_super_close_merged_cfdf8283a7_47aac544fd.jpg)
Essential Pharma acquires Renaissance Pharma Ltd
Renaissance Pharma Ltd, which was only founded in September 2023 with the licensing of the anti-GD2 antibody from St Jude Children's Research...
![](/fileadmin/_processed_/csm_NALFD_model_7770420204.png)
DefiniGEN and Atelerix prevent freezing damage in cell models
The agreement between the British companies combines DefiniGEN’s iPSC hepatocytes (Opti-Heps) with Atelerix's hydrogel preservation technology, which...
![](/fileadmin/_processed_/csm_Ignate1_SLAS_19d7db8119.png)
Semarion Ltd. wins Ignite SME award at SLAS Europe
Last night, the 19,000-member Society for Laboratory Automation and Screening (SLAS) has been presenting the Ignite Award for the most...
![](/fileadmin/_processed_/csm_tubulis_linker_ADC_web_bccd46dac0.jpg)
Tubulis from Munich doses first Patient with own ADC linker technology
Tubulis, based in Martinsried near Munich, announced today that the first patient has been treated in its first Phase 1/2a...
![](/fileadmin/_processed_/csm_Obstructive_Sleep_Apnea_Treatment_Genio_by_Nyxoah_083756dfdb.png)
Nyxoah signs a €37.5m loan with the European Investment Bank
Nyxoah SA (Euronext Brussels/Nasdaq: NYXH), located in Mont-Saint-Guibert, Belgium announced that it has signed a €37.5m loan facility agreement with...